p73-dependent apoptosis through death receptor: impairment by human cytomegalovirus infection.
The discovery of p73, a p53-related protein with various isotypes resulting from different promoter usage or splicing events, provided new insights into regulation of neurogenesis and tumorigenesis. Among p73 isoforms described thus far, TA-truncated molecules (DeltaN) appeared as key proteins according to their antagonistic activity against transcription factor activity of p53 family members. We previously showed that infection by human cytomegalovirus (HCMV) induced drug resistance and altered p53- and p73-dependent apoptosis of infected cells through accumulation of DeltaN-p73alpha. In accordance with the ability of p53 to induce apoptosis through death receptors, we asked whether p73 activation could compensate for p53 deficiency. We showed that p73 transcriptional activity sensitized cells to apoptosis through death receptors in a caspase-dependent pathway. Expression of the death-inducing signaling complex (DISC) proteins was unchanged, whereas p73 activation through either cisplatin treatment or ectopic overexpression induced up-regulation of Fas transcription and expression at cell surface. According to its ability to flood cells with DeltaN-p73alpha, HCMV inhibited p73-dependent Fas-mediated apoptosis, gaining an additional trick to favor its survival in the host cell. Owing to the involvement of p53- and p73-dependent death receptor signaling in development of the central nervous system, immune surveillance of neural cells, and sensitivity of tumors to drugs, our previous and present data prompt us to consider stabilization of DeltaN-p73alpha by HCMV as a possible mechanism in impairment of embryogenesis and in tumorigenesis.
Terrasson
Jérôme
J
Institut National de la Sante et de la Recherche Medicale U563, CHU Purpan, Toulouse, France.
Allart
Sophie
S
Martin
Hélène
H
Lulé
Jacqueline
J
Haddada
Hedi
H
Caput
Daniel
D
Davrinche
Christian
C
D048868:Adaptor Proteins, Signal Transducing / Q000096:biosynthesis; D017209:Apoptosis / Q000187:drug effects / Q000502:physiology*; D053446:CASP8 and FADD-Like Apoptosis Regulating Protein; D053181:Caspase 8; D020169:Caspases / Q000096:biosynthesis / Q000378:metabolism; D045744:Cell Line, Tumor; D002945:Cisplatin / Q000494:pharmacology; D003586:Cytomegalovirus Infections / Q000378:metabolism / Q000473:pathology*; D004268:DNA-Binding Proteins / Q000037:antagonists & inhibitors / Q000502:physiology*; D004789:Enzyme Activation; D053200:Fas-Associated Death Domain Protein; D016147:Genes, Tumor Suppressor; D006801:Humans; D047908:Intracellular Signaling Peptides and Proteins / Q000378:metabolism; D009474:Neurons / Q000378:metabolism / Q000473:pathology / Q000821:virology; D009687:Nuclear Proteins / Q000037:antagonists & inhibitors / Q000502:physiology*; D018124:Receptors, Tumor Necrosis Factor / Q000502:physiology*; D000072160:Tumor Protein p73; D025521:Tumor Suppressor Proteins; D019014:fas Receptor / Q000096:biosynthesis / Q000502:physiology
D048868:Adaptor Proteins, Signal Transducing; D053446:CASP8 and FADD-Like Apoptosis Regulating Protein; C506386:CFLAR protein, human; D004268:DNA-Binding Proteins; C505533:FADD protein, human; D053200:Fas-Associated Death Domain Protein; D047908:Intracellular Signaling Peptides and Proteins; D009687:Nuclear Proteins; D018124:Receptors, Tumor Necrosis Factor; C000606460:TP73 protein, human; D000072160:Tumor Protein p73; D025521:Tumor Suppressor Proteins; D019014:fas Receptor; C505530:CASP8 protein, human; D053181:Caspase 8; D020169:Caspases; D002945:Cisplatin